Cardiovascular medicine XXXX (CVM-HF) index as prognostic model for candidates to MitraClip therapy.

@entity1 @entity712 @entity339
UNASSIGNED: Transcatheter MitraClip repair is a new tool for the management of severe @entity339 in @entity1 at very high risk for conventional surgery. Aim of our study was reporting one-year clinical outcomes in candidates to MitraClip procedures, divided into three groups according to the cardiovascular medicine @entity712 (CVM-HF) index. The study population consists of 46 consecutive @entity1 , divided, in accordance with CVM-HF index, as follows: one @entity1 in the low-risk category (group A); 27 @entity1 in the medium-risk (group B) and 18 @entity1 in high-risk category (group C). The primary study endpoint was a combined of all-cause mortality and re-hospitalization rate. Secondary endpoints were all-cause mortality and cardiac mortality. @entity1 of group B and group C were compared. Regarding the primary endpoint, @entity1 in group C had significantly poorer outcomes than @entity1 in group B, with a 12-month survival freedom from events of 44.4   and 74.1  %, respectively (log-rank test, p  =  0.039); survival freedom from cardiac mortality was 100 and 83.3  % in group B and C, respectively (log-rank test, p  =  0.027). One-year survival free from re-hospitalization was 74.1  % in group B and 39.9  % in group C (log-rank test; p  =  0.036). Survival free from all-cause of mortality was 92.6 and 77.8  %, respectively (log-rank test; p  =  0.129). In our initial experience the CVM-HF index showed to be valuable for understanding if the @entity1 with advanced @entity712 and functional @entity339 can really benefit by MitraClip therapy.
